Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) – Quality of Life (QOL) assessment

X.Zhou; A.Segreti; D.Cella; D.Cameron; C.Geyer; M.Amonkar; S.Stein; M.Walker

首页> 外文期刊>European Journal of Cancer Supplements >Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) – Quality of Life (QOL) assessment

【24h】

Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) – Quality of Life (QOL) assessment

机译：拉帕替尼加卡培他滨与单用卡培他滨治疗ErbB2阳性转移性乳腺癌（MBC）–生活质量（QOL）评估

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2008年第7期|共2页
作者
X.Zhou; A.Segreti; D.Cella; D.Cameron; C.Geyer; M.Amonkar; S.Stein; M.Walker;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) – Quality of Life (QOL) assessment [J] . X.Zhou, A.Segreti, D.Cella, European Journal of Cancer Supplements . 2008,第7期

机译：拉帕替尼加卡培他滨与单用卡培他滨治疗ErbB2阳性转移性乳腺癌（MBC）–生活质量（QOL）评估
2. 2140 POSTER A comparison of lapatinib plus capecitabine versus capecitabine for quality-adjusted survival in metastatic breast cancer (MBC): A QTWiST analysis [J] . B.Sherrill, A.Allshouse, M.M.Amonkar, European Journal of Cancer Supplements . 2007,第4期

机译：2140海报拉帕替尼联合卡培他滨与卡培他滨治疗转移性乳腺癌（MBC）质量调整生存率的比较：QTWiST分析
3. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. [J] . Zhou X, Cella D, Cameron D Breast cancer research and treatment. . 2009,第3期

机译：拉帕替尼加卡培他滨与单用卡培他滨治疗HER2 +（ErbB2 +）转移性乳腺癌：生活质量评估。
4. Non-toxic approach for treatment of breast cancer and its cutaneous metastasis: Capecitabine (Xeloda™) enhanced photodynamic therapy in a murine tumor model [C] . Sanjay Anand, Anton Denisyuk, Taylor Bullock, Conference on optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy . 2018

机译：治疗乳腺癌及其皮肤转移的无毒方法：卡培他滨（Xeloda™）在小鼠肿瘤模型中增强了光动力治疗
5. Construct validity of the Quality of Life in Life-Threatening Illness-Patient questionnaire (QOLLTI-P) in cancer patients. [D] . Shahidi, Javad. 2010

机译：在威胁生命的疾病患者问卷中构建生活质量的效度（QOLLTI-P）。
6. Long-Term Disease Control with Lapatinib and Capecitabine in a Heavily Pretreated Patient with ErbB2-Positive Metastatic Breast Cancer [O] . Tina Idris, Peter Krippl, Uwe Lang, 2010

机译：拉帕替尼和卡培他滨在长期大量治疗的ErbB2阳性转移性乳腺癌患者中的长期疾病控制
7. PCN9 VALIDITY OF PROPORTIONAL HAZARDS (PH) WEIBULL MODELS FOR ANALYZING PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2+ (HER2+) METASTATIC BREAST CANCER (MBC) RECEIVING LAPATINIB PLUS CAPECITABINE (L+C) VERSUS CAPECITABINE ONLY (C-ONLY) [O] . Sofrygin O, Delea T, Tappenden P, 2008

机译：PCN9比例风险（PH）威布尔模型在分析曲妥珠单抗（TZ）耐药性ERBB2 +（HER2 +）转移性乳腺癌（MBC）患儿的无进展生存率（PFS）和总生存率（OS）方面的有效性C）仅卡西他滨（仅C）

Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) – Quality of Life (QOL) assessment

著录项

相似文献

相关主题

期刊订阅